Your browser doesn't support javascript.
loading
Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy.
Ravipati, Prasanth; Freese, Rebecca L; Royal, Virginie; Bu, Lihong; Canetta, Pietro; Gipson, Debbie; Kallash, Mahmood; Kiryluk, Krzysztof; Nast, Cynthia; Reich, Heather N; Rheault, Michelle N; Saha, Manish; Nachman, Patrick H.
Afiliação
  • Ravipati P; Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Freese RL; Division of Nephrology, Department of Medicine, University of Nebraska, Omaha, Nebraska, USA.
  • Royal V; Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.
  • Bu L; Department of Pathology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
  • Canetta P; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Gipson D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kallash M; Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Kiryluk K; Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
  • Nast C; Section of Pediatric Nephrology, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Reich HN; Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Rheault MN; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Saha M; Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
  • Nachman PH; Division of Pediatric Nephrology, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Kidney Int Rep ; 7(11): 2462-2473, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36531879
ABSTRACT

Introduction:

IgA nephropathy (IgAN) differs from other glomerular diseases by the frequently predominant lambda over kappa light chain deposition. Using the Cure Glomerulonephropathy (CureGN) IgAN cohort, we aimed to determine whether predominant lambda chain deposition is associated with worse clinical outcomes or histopathologic markers of more active disease.

Methods:

Patients were categorized based on the intensity of light chain staining. The lambda dominant (LD) group was defined by a difference in intensity score of lambda minus kappa ≥ 1+ and the kappa-lambda codominant (KL) group by a difference < 1+. We compared the clinical course of patients in each category from the time of kidney biopsy and time of enrollment into CureGN to the time of remission (proteinuria < 0.3 g/g), 50% reduction in estimated glomerular filtration rate (eGFR), or progression to end-stage kidney disease (ESKD). We also analyzed differences in histopathologic characteristics between the 2 groups.

Results:

Among 440 patients, we found no significant differences between groups in baseline clinical characteristics nor in rates of remission, 50% reduction in eGFR, or progression to ESKD. Patients in the LD group had a modestly greater frequency of IgG staining ≥ 1+. The biopsy results of 234 patients reviewed by CureGN pathologists revealed a greater frequency of endocapillary hypercellularity (51.1% vs. 36.3%, P = 0.04) in the LD group, but no other significant difference in histopathologic features.

Conclusion:

In IgAN, we found an association between lambda predominance and increased endocapillary hypercellularity, but no association with clinical outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article